Clinical associations between renal dysfunction and vascular events: A literature review

ARYA Atherosclerosis

Volumn 9, Issue 3, 2013, Pages 203-209

  Karbasi Afshar, Reza ^a   Saburi, Amin ^a   Taheri, Saeed ^b  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Dr Taheri Medical Research Group   (Iran)

Author keywords

Cardiovascular disorders; Dialysis; Myocardial infarction; Renal disease; Risk factor

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN A; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYOGLOBIN; RAPAMYCIN; TACROLIMUS; TROPONIN;

ANEMIA; BLEEDING; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTROPHY; HYPOALBUMINEMIA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT; MALNUTRITION; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; PERITONEAL DIALYSIS; PREVALENCE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); UREMIA;

EID: 84878081304     PISSN: 17353955     EISSN: 22516638     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17(7): 2034-47.
2. Sarnak MJ,Levey AS,Schoolwerth AC,Coresh J,Culleton B,Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42(5): 1050-65.
3. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting endstage renal disease therapy. Kidney Int 1995; 47(1): 186-92.
4. Yilmaz M, Unsal A, Oztekin E, Kesmezacar O, Kaptanogullari OH, Eren N. The prevalence of hypertension, valve calcification and left ventricular hypertrophy and geometry in peritoneal dialysis patients. Kidney Blood Press Res 2012; 35(6): 431-7.
5. Bakkaloglu SA, Borzych D, Soo H, I, Serdaroglu E, Buscher R, Salas P, et al. Cardiac geometry in children receiving chronic peritoneal dialysis: findings from the International Pediatric Peritoneal Dialysis Network (IPPN) registry. Clin J Am Soc Nephrol 2011; 6(8): 1926-33.
6. Tian JP, Wang T, Wang H, Cheng LT, Tian XK, Lindholm B, et al. The prevalence of left ventricular hypertrophy in Chinese hemodialysis patients is higher than that in peritoneal dialysis patients. Ren Fail 2008; 30(4): 391-400.
7. Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol 2000; 14(10-11): 898-902.
8. Paoletti E, Specchia C, Di MG, Bellino D, Damasio B, Cassottana P, et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant 2004; 19(7): 1829-34.
9. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996; 27(3): 347-54.
10. Tucker B, Fabbian F, Giles M, Thuraisingham RC, Raine AE, Baker LR. Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant 1997; 12(4): 724-8.
11. Hage FG, de Mattos AM, Khamash H, Mehta S, Warnock D, Iskandrian AE. QT prolongation is an independent predictor of mortality in end-stage renal disease. Clin Cardiol 2010; 33(6): 361-6.
12. Genovesi S, Rossi E, Nava M, Riva H, De FS, Fabbrini P, et al. A case series of chronic haemodialysis patients: mortality, sudden death, and QT interval. Europace 2013.
13. Covic A, Diaconita M, Gusbeth-Tatomir P, Covic M, Botezan A, Ungureanu G, et al. Haemodialysis increases QT(c) interval but not QT(c) dispersion in ESRD patients without manifest cardiac disease. Nephrol Dial Transplant 2002; 17(12): 2170-7.
14. Voiculescu M, Ionescu C, Ismail G. Frequency and prognostic significance of QT prolongation in chronic renal failure patients. Rom J Intern Med 2006; 44(4): 407-17.
15. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12(2): 218-25.
16. Nickolas TL, Khatri M, Boden-Albala B, Kiryluk K, Luo X, Gervasi-Franklin P, et al. The association between kidney disease and cardiovascular risk in a multiethnic cohort: findings from the Northern Manhattan Study (NOMAS). Stroke 2008; 39(10): 2876-9.
17. Cho AH, Lee SB, Han SJ, Shon YM, Yang DW, Kim BS. Impaired kidney function and cerebral microbleeds in patients with acute ischemic stroke. Neurology 2009; 73(20): 1645-8.
18. Saeed F, Kousar N, Qureshi K, Laurence TN. A review of risk factors for stroke in patients with chronic kidney disease. J Vasc Interv Neurol 2009; 2(1): 126-31.
19. Seliger SL, Gillen DL, Longstreth WT, Kestenbaum B, Stehman-Breen CO. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 2003; 64(2): 603-9.
20. Seliger SL, Gillen DL, Tirschwell D, Wasse H, Kestenbaum BR, Stehman-Breen CO. Risk factors for incident stroke among patients with end-stage renal disease. J Am Soc Nephrol 2003; 14(10): 2623-31.
21. Lee M, Saver JL, Chang KH, Liao HW, Chang SC, Ovbiagele B. Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ 2010; 341: c4249.
22. Toyoda K, Fujii K, Fujimi S, Kumai Y, Tsuchimochi H, Ibayashi S, et al. Stroke in patients on maintenance hemodialysis: a 22-year single-center study. Am J Kidney Dis 2005; 45(6): 1058-66.
23. Wada M, Nagasawa H, Iseki C, Takahashi Y, Sato H, Arawaka S, et al. Cerebral small vessel disease and chronic kidney disease (CKD): results of a cross-sectional study in community-based Japanese elderly. J Neurol Sci 2008; 272(1-2): 36-42.
24. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352(20): 2049-60.
25. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 2005; 51(2): 321-7.
26. Ovbiagele B. Impairment in glomerular filtration rate or glomerular filtration barrier and occurrence of stroke. Arch Neurol 2008; 65(7): 934-8.
27. Ni L, Lü J, Hou LB, Yan JT, Fan Q, Hui R, et al. Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese Stroke 2007; 38(12): 3287-8.
28. Tsagalis G, Akrivos T, Alevizaki M, Manios E, Stamatellopoulos K, Laggouranis A, et al. Renal dysfunction in acute stroke: an independent predictor of long-term all combined vascular events and overall mortality. Nephrol Dial Transplant 2009; 24(1): 194-200.
29. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145(4): 237-46.
30. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996; 28(5): 1328-428.
31. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 2007; 115(13): e356-e375.
32. Rabelink TJ, Truin G, de JP. Treatment of coronary artery disease in patients with renal failure. Nephrol Dial Transplant 2000; 15(Suppl 5): 117-21.
33. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339(12): 799-805.
34. Herzog CA, Ma J, Collins AJ. Outcome of dialysis patients receiving thrombolytic therapy for acute myocardial infarction. Circulation 1997; 96(Suppl 1): 1-202.
35. Herzog CA, Ma JZ, Collins AJ. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002; 106(17): 2207-11.
36. Sozio SM, Armstrong PA, Coresh J, Jaar BG, Fink NE, Plantinga LC, et al. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study. Am J Kidney Dis 2009; 54(3): 468-77.
37. Mattana J, Effiong C, Gooneratne R, Singhal PC. Outcome of stroke in patients undergoing hemodialysis. Arch Intern Med 1998; 158(5): 537-41.
38. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117(4): e25-146.
39. Evenson KR, Rosamond WD, Morris DL. Prehospital and in-hospital delays in acute stroke care. Neuroepidemiology 2001; 20(2): 65-76.
40. DeFrances CJ, Hall MJ. 2005 National Hospital Discharge Survey. Adv Data 2007; (385): 1-19.
41. Fabbian F, Casetta I, De GA, Pala M, Tiseo R, Portaluppi F, et al. Stroke and renal dysfunction: are we always conscious of this relationship? Clin Appl Thromb Hemost 2012; 18(3): 305-11.
42. Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004; 4(10): 1662-8.
43. Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009; 69(16): 2227-43.
44. Paoletti E, Amidone M, Cassottana P, Gherzi M, Marsano L, Cannella G. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial. Am J Kidney Dis 2008; 52(2): 324-30.
45. Paoletti E, Marsano L, Bellino D, Cassottana P, Cannella G. Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial. Transplantation 2012; 93(5): 503-8.